GPGA
CTKB icon

Grandeur Peak Global Advisors’s Cytek Biosciences CTKB Stock Holding History

Grandeur Peak Global Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-33,131
Closed -$222K – 133
2024
Q1 		$222K Hold
33,131
– – 0.02% 119
2023
Q4 		$302K Hold
33,131
– – 0.02% 110
2023
Q3 		$183K Hold
33,131
– – 0.01% 108
2023
Q2 		$283K Hold
33,131
– – 0.02% 108
2023
Q1 		$304K Buy
+33,131
New +$356K 0.02% 104

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Grandeur Peak Global Advisors's CTKB Position: Q2 2024 in Review

Grandeur Peak Global Advisors sold out of Cytek Biosciences (CTKB) in Q2 2024, closing a stake of 33,131 shares — an estimated $222K sold.

Grandeur Peak Global Advisors first reported a position in CTKB in Q1 2023 and held it in 5 quarters. The position peaked at $304K in Q1 2023. 128 funds tracked by Wall St. Rank hold CTKB as of Q2 2024.

  • Grandeur Peak Global Advisors reported no remaining Cytek Biosciences position as of Q2 2024 after selling out during the quarter.
  • Grandeur Peak Global Advisors sold 33,131 Cytek Biosciences shares in Q2 2024, an estimated $222K.
  • Grandeur Peak Global Advisors first reported a position in Cytek Biosciences in Q1 2023 and held it in 5 quarters.
  • Grandeur Peak Global Advisors's Cytek Biosciences position peaked at $304K in Q1 2023.
  • 128 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2024.

Based on Grandeur Peak Global Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.